SCHEMBL792516

SCHEMBL792516

CC(=O)c1ccc2c(C)c3n(c2c1)CN(C)CCC3

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.34
APOBEC3A P31941 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
TERT O14746 1/20 0.33
FABP4 P15090 1/20 0.33
ALOX5 P09917 1/20 0.33
GAA P10253 1/20 0.33
MAPK1 P28482 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TP53 P04637 2/20 0.32
HRH4 Q9H3N8 2/20 0.32
LMNA P02545 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
HPGD P15428 1/20 0.32
POLB P06746 1/20 0.32
THRB P10828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL792496 0.88 GAA (0.41) APOBEC3AAPOBEC3GFABP4ALOX5GAA
SCHEMBL792527 0.84 ALDH1A1 (0.41) APOBEC3AAPOBEC3GFABP4GAAMAPK1
SCHEMBL792524 0.79 FABP4 (0.45) FABP4GAAMAPK1ALDH1A1HPGD
SCHEMBL14572851 0.79 HTR2A (0.37) FABP4ALOX5L3MBTL1TP53ALDH1A1
SCHEMBL792539 0.77 DRD3 (0.41) TERTALDH1A1MAPT
SCHEMBL792525 0.72 GFER (0.41) ALOX5ALDH1A1MAPTHPGDPOLB
SCHEMBL792128 0.71 SIGMAR1 (0.32) APOBEC3AAPOBEC3GL3MBTL1TP53ALDH1A1
SCHEMBL792588 0.70 ALDH1A1 (0.42) FABP4ALDH1A1MAPTHPGD
SCHEMBL792066 0.67 MTNR1A (0.47) MAPK1MAPT
SCHEMBL13387223 0.65 MAPT (0.53) MAPK1L3MBTL1LMNAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor POLI, TERT, ZC3HAV1 HTR7 4776/4885APOBEC3A 2977/4885APOBEC3G 3279/4885
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 HTR7 4776/4885APOBEC3A 2977/4885APOBEC3G 3279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.